Product Image

Contributor Information

  • Name Ayham Alnabulsi
  • Institute Vertebrate Antibodies Limited

Tool Details

  • Tool name: Anti-DRAM1 [M3-P4B4]
  • Clone: M3-P4B4
  • Tool type: Antibodies
  • Tool sub-type: Primary antibody
  • Class: Monoclonal
  • Conjugate: Unconjugated
  • Reactivity: Human
  • Host: Mouse
  • Cancer type: Colorectal
  • Application: ELISA ; IHC ; IF ; WB
  • Strain: Balb/c
  • Description: DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.
  • Immunogen: Peptide Sequence - EKDYVYHVVS (amino acids 192 - 201)
  • Isotype: IgG1
  • Research area: Apoptosis and Programmed Cell Death ; Cancer ; Cell Cycle ; Cell Signaling & Signal Transduction ; Metabolism
  • Myeloma used: P3X63Ag8.653

  • For Research Use Only

Target Details

  • Target: Damage Regulated Autophagy Modulator 1 (DRAM1)
  • Target background: DRAM1 is significantly upregulated in colorectal cancer and significantly associated with prognosis.

Application Details

  • Application: ELISA ; IHC ; IF ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15°C to -25°C
  • Shipping conditions: Shipping at 4°C

Documentation

  • Available on request

References

  •   Brown et al. 2014. PLoS One. 9(3):e90776. PMID: 24608339.
  •   The expression and prognostic significance of retinoic acid metabolising enzymes in colorectal cancer.